Recent 8-K filings for CPHI
Highest-materiality recent filing
China Pharma terminates auditor BF Borgers after SEC denies its practice privilege; appoints Enrome LLP
- SEC issued Rule 102(e) Order against BF Borgers CPA PC on May 3, 2024, barring it from appearing or practicing before the SEC as an accountant.
- China Pharma terminated Borgers as independent auditor on May 7, 2024, with audit committee approval.
-
CPHI subsidiary acquires patent for $6.93M via stock; issues 12.6M shares
Hainan Helpson acquires patent for Prinsepia Utilis Esterol Sublingual Tablets from Xiaoyan Zhang.
-
China Pharma Holdings acquires topiroxostat nanoemulsion patent for $8.82M in stock
Transfer price of $8.82M paid in 12.6M restricted shares at $0.70/share; closing by Feb 20, 2026.
-
China Pharma Holdings shareholders approve reverse stock split up to 1:20 at annual meeting
Elected independent directors Gene Michael Bennett, Yingwen Zhang, Baowen Dong (3,500,418+ votes for each).
-
China Pharma subsidiary acquires Ipragliflozin patent for $9.8M in stock
Hainan Helpson enters Technology Transfer Agreement to acquire Ipragliflozin tablet patent from Juan Zhang.
-
China Pharma subsidiary to acquire captopril microcapsule patent for $6.3M in stock
Hainan Helpson subsidiary to receive Captopril microcapsule invention patent and preparation method from Lijie Tang.
-
China Pharma Holdings announces 1-for-10 reverse stock split effective April 15, 2025
Reverse stock split at ratio 1:10, effective April 15, 2025, trading to begin on split-adjusted basis.
-
China Pharma shareholders approve reverse stock split at 1:10–1:20; all directors elected
All five director nominees elected: Zhilin Li, Heung Mei Tsui (non-independent), Gene Michael Bennett, Yingwen Zhang, Baowen Dong (independent).
-
China Pharma rescinds Dec 12 securities purchase agreement; deal void ab initio
On Dec 23, 2024, company and an unnamed investor agreed to rescind the Dec 12 securities purchase agreement.
-
China Pharma enters into up to $600,000 at-the-market equity offering with institutional investor
SPA signed Dec 12, 2024 for up to $600K of common stock at market price, floor $0.15.
-
China Pharma extends convertible note maturity to Aug. 2025; minimum monthly payment cut 75%
Maturity date of $557,735 convertible note (Streeterville Capital) extended to August 19, 2025.
-
SEC issued Rule 102(e) Order against BF Borgers CPA PC on May 3, 2024, barring it from appearing or practicing before the SEC as an accountant.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.55 · Most common event other_material